NCT05400915View on ClinicalTrials.gov

Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 23, 2019

Primary Completion Date

December 13, 2021

Study Completion Date

June 13, 2022

Conditions
Gastric Cancer
Interventions
DRUG

Variltinib, Paclitaxel

Varlitinib will be administered orally to the study participants at doses 300mg, BID in combination with the weekly intravenous infusion of Paclitaxel for 3 weeks with a rest period of 1 week.

Trial Locations (1)

Unknown

Yonsei University Health System, Yonsei Cancer Center, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT05400915 - Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients | Biotech Hunter | Biotech Hunter